Search Details

Word: funding (lookup in dictionary) (lookup stats)
Dates: during 1990-1999
Sort By: most recent first (reverse)


Usage:

...derive income from consulting or serving as a board member, for example, you are eligible to open a Keogh by contributing, on a pretax basis, 25% of your earnings up to $30,000. Once the account is activated, you have until you pay your taxes next year to fund...

Author: /time Magazine | Title: Year-End Tax Tips | 11/22/1999 | See Source »

...careful, though, if your tax bracket will rise in retirement. Withdrawals from tax-deferred accounts get taxed as income. If you'll be retiring soon, new contributions might not have enough time to grow tax-deferred. You might be better served putting new savings into a tax-efficient mutual fund, like an index fund. When you cash that in after one year, you pay the capital-gains rate on your earnings, typically lower than the income-tax rate you pay on IRA withdrawals...

Author: /time Magazine | Title: Year-End Tax Tips | 11/22/1999 | See Source »

RESIGNED. MICHEL CAMDESSUS, 67, managing director of the International Monetary Fund who helped stabilize Mexico and Asia in recent crises; in mid-term, for personal reasons; in Washington...

Author: /time Magazine | Title: Milestones Nov. 22, 1999 | 11/22/1999 | See Source »

...joined Justice's suit, so the software giant's lobbying strategies are expanding. Microsoft's tactics range from hiring close pals of several A.G.s to sending a key official to speak to a small town's Chamber of Commerce. State officials tell TIME that the company is also helping fund a new Republican attorneys-general group in Washington...

Author: /time Magazine | Title: The Microsoft Antitrust Case | 11/22/1999 | See Source »

Schering-Plough argues that additional patent years are only fair. Claritin was stuck in the Food and Drug Administration approval pipeline longer than many drugs, it claims, with the clock ticking on its 17-year patent. Schering-Plough also says Claritin profits help fund research for new drugs. But, its opponents counter, what about Claritin patients--who pay as much as $2.66 a dose instead of the 50[cents] or less they would pay, analysts figure, if a generic version of the drug were available? If the patent expires on time, according to a University of Minnesota study funded...

Author: /time Magazine | Title: The Claritin Case | 11/22/1999 | See Source »

Previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | Next